Evaluation Study of SPOTme® Skin Cancer Screenings

Overview

This study evaluates the impact of the AAD SPOTme® skin cancer screening events on attendees' skin cancer prevention and detection behaviors. This study will also evaluate whether an educational intervention will improve post-screening engagement of attendees with dermatologists.

Full Title of Study: “Evaluation Study of SPOTme® Skin Cancer Screenings”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: Single (Participant)
  • Study Primary Completion Date: October 1, 2018

Detailed Description

Despite tremendous growth in both the interest and volume of skin cancer screenings at the national level, the actual utility and impact of the AAD SPOT me™ skin cancer screening programs have not been fully evaluated. This study will address this knowledge gap. Early detection is vital in the fight against skin cancer, the most common cancer in the United States. While the effects of skin cancer can be devastating, this disease is highly treatable when detected early. This study evaluates the impact of the AAD SPOTme® skin cancer screening events on attendees' skin cancer prevention and detection behaviors. This study will also evaluate whether an educational intervention will improve post-screening engagement of attendees with dermatologists.

Interventions

  • Behavioral: Intervention Arm
    • Individuals randomized to the intervention group will receive skin cancer screening educational materials.
  • Other: AAD SPOTmeⓇ skin cancer screening
    • All study participants will have participated in the AAD SPOTmeⓇ skin cancer screening program in either 2016 or 2017.

Arms, Groups and Cohorts

  • Experimental: Intervention Arm 1
    • Individuals randomized to intervention group 1 will have participated in the AAD SPOTmeⓇ skin cancer screening program in either 2016 or 2017 AND will receive additional skin cancer screening educational materials.
  • Experimental: Intervention Arm 2
    • Individuals randomized to intervention group 2 will have participated in the AAD SPOTmeⓇ skin cancer screening program in either 2016 or 2017 only.

Clinical Trial Outcome Measures

Primary Measures

  • Completion of a physician skin examination
    • Time Frame: Baseline
    • Self-report of a physician skin examination will be defined as a health care provider examining the patient’s entire body for any sign of skin cancer during the period following patient’s receipt of an AAD SPOTme® skin cancer screening to the baseline assessment.

Secondary Measures

  • Completion of a physician skin examination
    • Time Frame: 6 months
    • Self-report of a physician skin examination will be defined as a health care provider examining the patient’s entire body for any sign of skin cancer during the 3 months prior to the 6-month follow up assessment
  • Patient thorough skin self-examination (TSSE)
    • Time Frame: 6 months
    • Self-report of patient thorough skin self-examination (TSSE) will be defined as performing at least one TSSE during the 3 months prior to the 6-month follow up assessment
  • Patient attitude towards sun protection
    • Time Frame: 6 months
    • Self-report of patient attitude towards use of sun protection will be defined by likelihood of engaging in sun protection practices in the year following the 6-month follow up assessment

Participating in This Clinical Trial

Inclusion Criteria

  • Participated in the American Academy of Dermatology national screening program in 2016 or 2017 – Have a presumptive diagnosis (screening, non-confirmed) of melanoma – Have provided the AAD with permission to be re-contacted – Have provided the AAD with an email address – Aged 18 years or older – Able to read English Exclusion Criteria:

  • None

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Harvard School of Public Health (HSPH)
  • Collaborator
    • American Academy of Dermatology (AAD)
  • Provider of Information About this Clinical Study
    • Principal Investigator: Alan Geller, MPH, RN – Harvard School of Public Health (HSPH)
  • Overall Official(s)
    • Alan Geller, MPH, RN, Principal Investigator, Harvard TH Chan School of Public Health

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.